Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Capricor Therapeutics, Inc. has 58.11M shares outstanding.

As of June 30, 2026, Capricor Therapeutics, Inc. maintains a current ratio of 7.35, meaning it holds 7.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Capricor Therapeutics, Inc. posted a negative return on equity (ROE) of -73.70, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -51.53, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 213.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Capricor Therapeutics, Inc. recorded 1,400.48 in income tax expense. The company reported a pretax loss of -113.28M and -113.28M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Capricor Therapeutics, Inc. generated - - in revenue and converted that into -113.28M in net income, yielding earnings per share of -2.16. EBITDA reached -41.29M, while operating income came in at -118.30M.

As of June 30, 2026, Capricor Therapeutics, Inc. holds 208.26M in cash and equivalents against 79.69M in total debt, resulting in a net debt position of -18.32M. Total book value stands at 215.52M, with working capital of 183.08M providing operational flexibility.

Capricor Therapeutics, Inc. produced -91.03M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -22.57M in capital expenditures, free cash flow totaled -113.59M - equivalent to -2.16 per share.

Capricor Therapeutics, Inc.'s most recent stock split took place on June 5, 2019 with a 10:1 split ratio.